Key factors
sym | KTRA |
exch | US |
MCap | 3630.52K |
Beta | 0.589 |
EPS | -5.22 |
Div date | 0000-00-00 |
Yesterday
sym | KTRA |
exch | US |
close | 0.104 |
50 Day MA | 0.112 |
200 Day MA | 2.134 |
52 Week High | 5.98 |
52 Week Low | 0.081 |
Target Price | 14.0 |
Market Cap Mln | 3.630 |
Share statistics
Shares Outstanding | 39.03M |
Shares Float | 39.02M |
Percent Institutions | 0.62 |
PercentInsiders | 0.208 |
SharesShort | 2191.68K |
Short Ratio | 0.18 |
Shares Short Prior Month | 411.08K |
Short Percent | 5.620 |
Income
EBITDA | -10.5M |
Diluted Eps TTM | -5.22 |
earning
EPS Estimate Current Year | -0.46 |
EPS Estimate Next Year | -0.38 |
Earnings Share | -5.22 |
Dividend
Dividend Date | 2019-05-08 |
Last Split Date | 2022-11-14 |
Last Split Factor | 1:50 |
business
Enterprise Value Ebitda | -1.23 |
Book Value /share | -1.02 |
Price Book MRQ | 7.807 |
ReturnOnAssetsTTM | -1.12 |
ReturnOnEquityTTM | -3.29 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US49720K1016 |
CIK | 1498382 |
Code | KTRA |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-03-22 |
info
Fiscal Year End | June |
Full Time Employees | 2.0 |
IPODate | 2013-02-22 |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Kintara Therapeutics Inc |
Address | 9920 Pacific Heights Blvd, San Diego, CA, United States, 92121 |
Country Name | USA |
Phone | 858 350 4364 |
Web URL | https://www.kintara.com |
Logo URL | /img/logos/US/KTRA.png |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.